Emergence of Hyper-Epidemic Clones of Enterobacterales Clinical Isolates Co-Producing KPC and Metallo-Beta-Lactamases during the COVID-19 Pandemic.
COVID-19
Carbapenemase
Enterobacterales
ST307
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
18 Mar 2023
18 Mar 2023
Historique:
received:
23
02
2023
revised:
13
03
2023
accepted:
16
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
The global spread of carbapenemase-producing Enterobacterales has become an epidemiological risk for healthcare systems by limiting available antimicrobial treatments. The COVID-19 pandemic worsened this scenario, prompting the emergence of extremely resistant microorganisms. Between March 2020 and September 2021, the NRL confirmed 82 clinical Enterobacterales isolates harboring a combination of Isolates were submitted from 28 hospitals located in seven provinces and Buenos Aires City, including 77 The MDDS tests using ceftazidime-avibactam/EDTA and aztreonam/boronic acid disks improved phenotypic classification as dual producers. The successful high-risk clones of
Sections du résumé
BACKGROUND
BACKGROUND
The global spread of carbapenemase-producing Enterobacterales has become an epidemiological risk for healthcare systems by limiting available antimicrobial treatments. The COVID-19 pandemic worsened this scenario, prompting the emergence of extremely resistant microorganisms.
METHODS
METHODS
Between March 2020 and September 2021, the NRL confirmed 82 clinical Enterobacterales isolates harboring a combination of
RESULTS
RESULTS
Isolates were submitted from 28 hospitals located in seven provinces and Buenos Aires City, including 77
CONCLUSIONS
CONCLUSIONS
The MDDS tests using ceftazidime-avibactam/EDTA and aztreonam/boronic acid disks improved phenotypic classification as dual producers. The successful high-risk clones of
Identifiants
pubmed: 36986401
pii: pathogens12030479
doi: 10.3390/pathogens12030479
pmc: PMC10052147
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Environ Sci Pollut Res Int. 2016 Mar;23(5):4953-8
pubmed: 26782324
Diagn Microbiol Infect Dis. 2015 Nov;83(3):298-304
pubmed: 26341707
Emerg Infect Dis. 2008 Jul;14(7):1178-80
pubmed: 18598660
Clin Infect Dis. 2021 Apr 8;72(7):e169-e183
pubmed: 33106864
Int J Antimicrob Agents. 2013 Jun;41(6):524-6
pubmed: 23622882
Antimicrob Agents Chemother. 2020 Sep 21;64(10):
pubmed: 32747358
Clin Microbiol Infect. 2011 Oct;17(10):1520-4
pubmed: 21851480
Microb Drug Resist. 2021 Feb;27(2):204-211
pubmed: 32614722
Rev Argent Microbiol. 2022 Oct-Dec;54(4):288-292
pubmed: 35753832
PLoS One. 2019 Sep 9;14(9):e0221960
pubmed: 31498841
BMC Infect Dis. 2022 Jul 7;22(1):603
pubmed: 35799130
J Antimicrob Chemother. 2017 Dec 01;72(12):3283-3287
pubmed: 29029114
BMC Microbiol. 2020 Nov 12;20(1):345
pubmed: 33183231
Emerg Infect Dis. 2022 Nov;28(11):1-8
pubmed: 36286547
Eur J Clin Microbiol Infect Dis. 2021 Aug;40(8):1755-1759
pubmed: 33595756
Clin Microbiol Rev. 2020 Nov 11;34(1):
pubmed: 33177185
Am J Infect Control. 2020 Dec;48(12):1533-1536
pubmed: 33011336
J Glob Antimicrob Resist. 2014 Dec;2(4):327-329
pubmed: 27873696
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33115847
J Glob Antimicrob Resist. 2014 Dec;2(4):344-345
pubmed: 27873702
J Glob Antimicrob Resist. 2019 Sep;18:238-242
pubmed: 31202977
Antimicrob Agents Chemother. 2015 Oct 26;60(1):332-42
pubmed: 26503660
Sci Rep. 2021 Jul 7;11(1):14041
pubmed: 34234222
Infect Control Hosp Epidemiol. 2022 Jan;43(1):12-25
pubmed: 34473013
J Glob Antimicrob Resist. 2022 Sep;30:222-227
pubmed: 35764216
Clin Infect Dis. 2021 Jun 1;72(11):1871-1878
pubmed: 32427286
Clin Microbiol Infect. 2014 Oct;20(10):O633-5
pubmed: 24476498
Infect Drug Resist. 2021 Oct 21;14:4363-4374
pubmed: 34707380
Int J Antimicrob Agents. 2018 Sep;52(3):331-337
pubmed: 29654892
Microb Drug Resist. 2018 Sep;24(7):958-965
pubmed: 29236574